[{"address1": "9704 Medical Center Drive", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "301 251 5172", "fax": "301 251 5321", "website": "https://www.macrogenics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 \u00d7 CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B \u00d7 CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.", "fullTimeEmployees": 339, "companyOfficers": [{"maxAge": 1, "name": "Dr. Scott  Koenig M.D., Ph.D.", "age": 72, "title": "President, CEO & Director", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 1199494, "exercisedValue": 0, "unexercisedValue": 459000}, {"maxAge": 1, "name": "Mr. James  Karrels", "age": 57, "title": "Senior VP, CFO & Corporate Secretary", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 693306, "exercisedValue": 0, "unexercisedValue": 162000}, {"maxAge": 1, "name": "Dr. Stephen L. Eck M.D., Ph.D.", "age": 69, "title": "Senior VP of Clinical Development & Chief Medical Officer", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 766848, "exercisedValue": 0, "unexercisedValue": 180000}, {"maxAge": 1, "name": "Mr. Eric Blasius Risser", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 651362, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thomas M. Spitznagel Ph.D.", "age": 57, "title": "Senior Vice President of Technical Operations", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 550974, "exercisedValue": 204497, "unexercisedValue": 490417}, {"maxAge": 1, "name": "Dr. Ezio  Bonvini M.D.", "age": 70, "title": "Senior VP of Research & Chief Scientific Officer", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 612208, "exercisedValue": 264031, "unexercisedValue": 199063}, {"maxAge": 1, "name": "Mr. Jeffrey Stuart Peters J.D.", "age": 53, "title": "Senior VP, General Counsel & Corporate Compliance Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Beth  Smith", "title": "VP, Controller & Treasurer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 3, "compensationRisk": 6, "shareHolderRightsRisk": 7, "overallRisk": 5, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.16, "open": 3.17, "dayLow": 3.0799, "dayHigh": 3.365, "regularMarketPreviousClose": 3.16, "regularMarketOpen": 3.17, "regularMarketDayLow": 3.0799, "regularMarketDayHigh": 3.365, "beta": 2.076, "forwardPE": -1.1650136, "volume": 714773, "regularMarketVolume": 714773, "averageVolume": 593193, "averageVolume10days": 611080, "averageDailyVolume10Day": 611080, "bid": 2.4, "ask": 3.98, "bidSize": 200, "askSize": 200, "marketCap": 202725776, "fiftyTwoWeekLow": 2.91, "fiftyTwoWeekHigh": 21.88, "priceToSalesTrailing12Months": 1.4344245, "fiftyDayAverage": 3.3662, "twoHundredDayAverage": 5.2303, "currency": "USD", "enterpriseValue": 36462936, "profitMargins": -0.69071, "floatShares": 51742814, "sharesOutstanding": 62763400, "sharesShort": 5184674, "sharesShortPriorMonth": 5214021, "sharesShortPreviousMonthDate": 1732838400, "dateShortInterest": 1735603200, "sharesPercentSharesOut": 0.082600005, "heldPercentInsiders": 0.026530001, "heldPercentInstitutions": 0.93651, "shortRatio": 10.82, "shortPercentOfFloat": 0.1014, "impliedSharesOutstanding": 62763400, "bookValue": 1.913, "priceToBook": 1.6884475, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "earningsQuarterlyGrowth": 2.208, "netIncomeToCommon": -97617000, "trailingEps": -1.57, "forwardEps": -2.41, "enterpriseToRevenue": 0.258, "enterpriseToEbitda": -0.366, "52WeekChange": -0.76319647, "SandP52WeekChange": 0.23809385, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MGNX", "underlyingSymbol": "MGNX", "shortName": "MacroGenics, Inc.", "longName": "MacroGenics, Inc.", "firstTradeDateEpochUtc": 1381411800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "322da638-92af-3f5e-9fb0-7915224804a7", "messageBoardId": "finmb_600911", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.23, "targetHighPrice": 14.0, "targetLowPrice": 4.0, "targetMeanPrice": 7.375, "targetMedianPrice": 7.0, "recommendationKey": "none", "numberOfAnalystOpinions": 8, "totalCash": 200363008, "totalCashPerShare": 3.192, "ebitda": -99708000, "totalDebt": 34100000, "quickRatio": 3.526, "currentRatio": 3.746, "totalRevenue": 141328992, "debtToEquity": 28.401, "revenuePerShare": 2.264, "returnOnAssets": -0.22147, "returnOnEquity": -0.62167, "grossProfits": -51298000, "freeCashflow": -21178250, "operatingCashflow": -58003000, "earningsGrowth": 2.205, "revenueGrowth": 9.648, "grossMargins": -0.36297, "ebitdaMargins": -0.7055, "operatingMargins": 0.48949, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-25"}]